Clinical Trial: A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07925190) titled 'A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients' on Oct. 28.

Brief Summary: A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Acute Myeloblastic Leukaemia

Intervention: DRUG: Mesutoclax (ICP-248)

125 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.

DRUG: Azacitidine (AZA)

75 mg/m2, Day 1-7 or Day 1-5 and Day 8-9 of each...